Intact Investment Management Inc. Buys 2,520 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Intact Investment Management Inc. grew its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 79.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,700 shares of the medical research company's stock after buying an additional 2,520 shares during the period. Intact Investment Management Inc.'s holdings in IQVIA were worth $1,120,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in IQV. Raymond James Financial Inc. purchased a new stake in shares of IQVIA in the 4th quarter valued at $236,120,000. FMR LLC boosted its stake in shares of IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock valued at $684,213,000 after purchasing an additional 804,963 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in shares of IQVIA in the 3rd quarter valued at $147,683,000. JPMorgan Chase & Co. raised its holdings in IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock valued at $437,378,000 after buying an additional 583,396 shares during the last quarter. Finally, Nordea Investment Management AB raised its holdings in IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock valued at $277,908,000 after buying an additional 452,029 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

Analyst Ratings Changes

A number of research firms recently commented on IQV. Stephens began coverage on shares of IQVIA in a report on Friday, December 20th. They set an "overweight" rating and a $250.00 price target for the company. Stifel Nicolaus lowered their price target on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a report on Friday, February 7th. Robert W. Baird lowered their price target on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating for the company in a report on Tuesday, January 21st. William Blair reiterated an "outperform" rating on shares of IQVIA in a report on Wednesday, December 11th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a report on Tuesday, February 18th. Five analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $249.05.

Remove Ads

IQVIA Stock Down 0.9 %

NYSE IQV traded down $1.75 during trading hours on Wednesday, reaching $186.80. 1,008,388 shares of the company's stock traded hands, compared to its average volume of 1,227,564. The firm has a market cap of $32.93 billion, a PE ratio of 24.91, a PEG ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 52-week low of $179.28 and a 52-week high of $256.34. The firm has a 50-day simple moving average of $196.06 and a 200 day simple moving average of $209.52.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.